HC Wainwright Reduces Earnings Estimates for Alpha Cognition

Alpha Cognition Inc. (NASDAQ:ACOG) – Equities researchers at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for shares of Alpha Cognition in a report released on Friday, May 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.33) per share for the quarter, down from their previous forecast of ($0.32). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Alpha Cognition’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Alpha Cognition’s FY2026 earnings at ($1.08) EPS, Q1 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.32) EPS.

Alpha Cognition (NASDAQ:ACOG) last announced its earnings results on Thursday, May 14th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.04. Alpha Cognition had a negative return on equity of 58.35% and a negative net margin of 232.23%.The firm had revenue of $3.53 million for the quarter, compared to analysts’ expectations of $3.42 million.

A number of other research analysts have also issued reports on the stock. Craig Hallum started coverage on shares of Alpha Cognition in a report on Friday, April 17th. They issued a “buy” rating and a $14.00 target price on the stock. Wall Street Zen lowered shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $16.00.

Alpha Cognition Stock Up 0.5%

ACOG opened at $5.88 on Wednesday. The firm has a market cap of $128.01 million, a P/E ratio of -4.36 and a beta of 2.38. The business’s fifty day simple moving average is $6.07 and its 200 day simple moving average is $5.90. Alpha Cognition has a 52 week low of $4.50 and a 52 week high of $11.54.

Institutional Trading of Alpha Cognition

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACOG. Alyeska Investment Group L.P. acquired a new stake in shares of Alpha Cognition in the fourth quarter worth approximately $2,372,000. AWM Investment Company Inc. boosted its holdings in shares of Alpha Cognition by 52.6% in the 4th quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company’s stock valued at $10,869,000 after purchasing an additional 576,516 shares during the last quarter. Opaleye Management Inc. boosted its holdings in shares of Alpha Cognition by 1,698.5% in the 4th quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock valued at $13,460,000 after purchasing an additional 1,955,642 shares during the last quarter. Cable Car Capital LP grew its stake in shares of Alpha Cognition by 68.8% during the 2nd quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock valued at $8,108,000 after buying an additional 354,278 shares during the period. Finally, Ikarian Capital LLC increased its holdings in shares of Alpha Cognition by 11.6% during the 4th quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company’s stock worth $6,866,000 after buying an additional 110,000 shares during the last quarter.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.